PT  - JOURNAL ARTICLE
AU  - Tan, Vanessa Y
AU  - Bull, Caroline J
AU  - Biernacka, Kalina M
AU  - Teumer, Alexander
AU  - Corbin, Laura
AU  - Dudding, Tom
AU  - Sanderson, Eleanor
AU  - Qi, Qibin
AU  - Kaplan, Robert C
AU  - Rotter, Jerome I
AU  - Friedrich, Nele
AU  - Völker, Uwe
AU  - Mayerle, Julia
AU  - Perks, Claire M
AU  - Holly, Jeff MP
AU  - Timpson, Nicholas J
TI  - Estimating the effect of lipids on IGF axis and subsequent breast cancer risk
AID  - 10.1101/2020.06.04.20122630
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.04.20122630
4099  - http://medrxiv.org/content/early/2020/06/07/2020.06.04.20122630.short
4100  - http://medrxiv.org/content/early/2020/06/07/2020.06.04.20122630.full
AB  - Circulating lipids have been associated with breast cancer (BCa). This association may, in part, be due to an effect of lipids on insulin-like growth factors (IGFs), which have been reliably associated with BCa. In two-sample Mendelian randomization (MR) analyses, we found that low density lipoprotein (LDL-C) was associated with IGFBP-3 (beta:0.08 SD; 95%CI:0.02,0.15; p = 0.01, per SD increase in LDL-C) and IGFBP-3 was associated with postmenopausal BCa (OR:1.09; 95%CI:1.00,1.19; p = 0.05, per SD increase in IGFBP-3). We also found that triglycerides were associated with IGF-I (beta:-0.13SD; 95%CI:-0.22,-0.03, per SD increase in triglycerides) and that IGF-I was associated with overall BCa (OR:1.10;95%CI:1.02,1.18, per SD increase in IGF-I). Taken together, these results suggest that IGFBP-3 may be a potential causal step between LDL-C and postmenopausal BCa and IGF-I a potential causal for triglycerides. Our two-step MR results build on evidence linking circulating lipids and IGFs with BCa, however, multivariable MR analyses are currently unable to support this relationship due to weak instruments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was specifically supported by the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) (MC_UU_12013/3) and by a Cancer Research UK Programme Grant (The Integrative Cancer Epidemiology Programme, ICEP) (C18281/A19169). VT, KMB, CMP, JMPH, NJT are supported by ICEP (C18281/A19169). NJT is a Wellcome Trust Investigator (202802/Z/16/Z) and works within the University of Bristol NIHR Biomedical Research Centre (BRC). LJC is supported by NJT Wellcome Trust Investigator grant (202802/Z/16/Z). NJT and LJC work in the MRC IEU at the University of Bristol which is supported by the MRC (MC_UU_00011) and the University of Bristol. TD received support from Wellcome (grant ref 201268/Z/16/Z) and is now funded by the NIHR as an Academic Clinical Fellow. QQ is supported by a Scientist Development Award (K01HL129892) from the NHLBI. JR is supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This publication is the work of the authors who will serve as guarantors for the contents of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank received ethical approval from the Research Ethics Committee (REC reference for UK Biobank is 11/NW/0382).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors